PMID- 29081615
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 0976-500X (Print)
IS  - 0976-5018 (Electronic)
IS  - 0976-500X (Linking)
VI  - 8
IP  - 3
DP  - 2017 Jul-Sep
TI  - Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease.
PG  - 87-91
LID - 10.4103/jpp.JPP_45_17 [doi]
AB  - Soluble guanylate cyclase (sGC) is an important transducing enzyme of cyclic 
      guanosine monophosphate (cGMP) signaling pathway in striatum which has been 
      considered as a potential target for the treatment of Parkinson's disease. 
      Etiology of Parkinson's disease is multifactorial, finally resulting in abnormal 
      proteinopathies causing degeneration of nigrostriatal pathways. Understanding the 
      pathological basis of Parkinson's disease at molecular level is still an 
      achievable target for the researchers and clinical practitioners. sGCs may be one 
      of the causative factors resulting in Parkinson's disease due to glutamate 
      toxicity or other event. This review presents the literature from articles of 
      past five decades nearly as still this enzyme protein and its role in Parkinson's 
      disease is not that clearly understood or presented till date. Recent 
      interventions of this protein inhibition in the treatment of Parkinson's disease 
      preclinically gave a chance to review the literature about this enzyme and its 
      correlation with factors causing Parkinson's disease. We explored literature 
      using PubMed and EMBASE for the role of sGC in Parkinson's disease. Databases 
      were searched using the following terms: Parkinson's disease, neurotoxins, 
      guanylate cyclase, sGC-cGMP pathway, and neurodegeneration. This review listed 
      out the factors that have probability for stimulating sGC which already have been 
      listed as a neurotoxins causing Parkinson's disease.
FAU - Ghanta, Mohankrishna
AU  - Ghanta M
AD  - Department of Pharmacology, Sri Ramachandra Medical College and Research 
      Institute, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India.
FAU - Panchanathan, Elango
AU  - Panchanathan E
AD  - Department of Pharmacology, Sri Ramachandra Medical College and Research 
      Institute, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India.
FAU - Lakkakula, Bhaskar V K S
AU  - Lakkakula BVKS
AD  - Department of Molecular Genetics, Research Division, Sickle Cell Institute 
      Chhattisgarh, Raipur, Chhattisgarh, India.
FAU - Narayanaswamy, Anbumani
AU  - Narayanaswamy A
AD  - Department of Microbiology, Sri Ramachandra Medical College and Research 
      Institute, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Pharmacol Pharmacother
JT  - Journal of pharmacology & pharmacotherapeutics
JID - 101552113
PMC - PMC5642137
OTO - NOTNLM
OT  - Guanylate cyclase inhibitors
OT  - Parkinsonism
OT  - guanylyl cyclase
OT  - neurodegeneration
OT  - neurotoxins
COIS- There are no conflicts of interest.
EDAT- 2017/10/31 06:00
MHDA- 2017/10/31 06:01
PMCR- 2017/07/01
CRDT- 2017/10/31 06:00
PHST- 2017/10/31 06:00 [entrez]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2017/10/31 06:01 [medline]
PHST- 2017/07/01 00:00 [pmc-release]
AID - JPP-8-87 [pii]
AID - 10.4103/jpp.JPP_45_17 [doi]
PST - ppublish
SO  - J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):87-91. doi: 10.4103/jpp.JPP_45_17.